Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births

Selective serotonin reuptake inhibitor use during early pregnancy and congenital malformations: a systematic review and meta-analysis of cohort studies of more than 9 million births

Abstract Background In 2005, the FDA cautioned that exposure to paroxetine, a selective serotonin reuptake inhibitor (SSRI), during the first trimester of pregnancy may increase the risk of cardiac malformations. Since then, the association between maternal use of SSRIs during pregnancy and congenit...

Full description

Bibliographic Details
Main Authors: Shan-Yan Gao, Qi-Jun Wu, Ce Sun, Tie-Ning Zhang, Zi-Qi Shen, Cai-Xia Liu, Ting-Ting Gong, Xin Xu, Chao Ji, Dong-Hui Huang, Qing Chang, Yu-Hong Zhao
Format: Article
Language:English
Published: BMC 2018-11-01
Series:BMC Medicine
Subjects:
Antidepressant
Congenital malformations
Cohort studies
Pregnancy
Serotonin uptake inhibitors
Meta-analysis
Online Access:http://link.springer.com/article/10.1186/s12916-018-1193-5

Internet

http://link.springer.com/article/10.1186/s12916-018-1193-5

Similar Items